When was the influenza vaccine discovered. How did early vaccine attempts differ from modern flu shots. What breakthroughs led to effective influenza immunization. How have influenza vaccines evolved over time.

The Early Days: Mistaken Causes and Ineffective Treatments

The history of influenza vaccination began long before an effective vaccine was developed. In the late 19th and early 20th centuries, scientists mistakenly believed influenza was caused by bacteria rather than a virus. This led to unsuccessful early vaccine attempts during the devastating 1918 influenza pandemic.

In 1892, German scientist Richard Pfeiffer isolated a bacterium he named “bacillus influenzae” from flu patients, believing it to be the cause of the disease. This misunderstanding persisted for decades, hindering progress toward an effective vaccine.

The 1918 Pandemic and Failed Vaccine Efforts

The 1918 H1N1 influenza pandemic, often called “the mother of all pandemics,” highlighted the urgent need for an influenza vaccine. This particularly virulent strain infected an estimated 500 million people worldwide and killed between 20-50 million.

Researchers in the United States and Europe raced to develop a vaccine during the pandemic. Their efforts produced hundreds of thousands of doses, but these were ineffective because they targeted bacteria rather than the true viral cause of influenza.

Breakthrough: Identifying the Influenza Virus

The path to an effective influenza vaccine began in 1933 when British scientists first isolated the influenza virus. This crucial discovery allowed researchers to finally target the correct pathogen in their vaccine development efforts.

How did the identification of the influenza virus change vaccine research?

The isolation of the influenza virus in 1933 revolutionized vaccine research by:

• Providing the correct target for vaccine development
• Allowing scientists to grow the virus in laboratory settings
• Enabling researchers to study the virus’s structure and behavior
• Paving the way for animal studies and early human trials

The First Influenza Vaccines: 1940s Breakthroughs

Building on the discovery of the influenza virus, researchers made rapid progress in the 1930s and early 1940s. The first influenza vaccines for widespread use were developed during World War II, with the U.S. military playing a key role in their testing and implementation.

Key milestones in early influenza vaccine development:

1. 1936: Researchers demonstrate that the influenza virus can be grown in embryonated chicken eggs
2. 1942: First large-scale influenza vaccine trials conducted by the U.S. military
3. 1945: The first influenza vaccine is licensed for civilian use in the United States

These early vaccines, while a significant step forward, were monovalent – meaning they only protected against a single strain of influenza virus. This limited their effectiveness, as influenza viruses are known for their rapid mutation and ability to produce new strains.

Evolving Vaccine Technology: From Monovalent to Multivalent Formulations

As understanding of influenza viruses grew, so did the sophistication of vaccines designed to combat them. Researchers recognized the need to protect against multiple strains simultaneously, leading to the development of bivalent and eventually trivalent vaccines.

How did influenza vaccines evolve to protect against multiple strains?

The evolution of influenza vaccines progressed as follows:

• 1940s: Monovalent vaccines (single strain)
• 1950s: Bivalent vaccines (two strains)
• 1970s: Trivalent vaccines (three strains)
• 2010s: Quadrivalent vaccines (four strains)

This progression reflects scientists’ growing understanding of influenza virus diversity and the need to provide broader protection against circulating strains.

The Global Influenza Surveillance System: Guiding Vaccine Development

A critical development in the history of influenza vaccination was the establishment of a global surveillance system to monitor circulating influenza strains. This system, initiated by the World Health Organization (WHO) in 1952, has been instrumental in guiding the composition of seasonal influenza vaccines.

How does global influenza surveillance impact vaccine development?

The WHO Global Influenza Surveillance and Response System (GISRS) plays a crucial role by:

• Monitoring circulating influenza strains worldwide
• Identifying emerging strains with pandemic potential
• Recommending which strains should be included in seasonal vaccines
• Providing virus samples to vaccine manufacturers
• Coordinating rapid response to influenza outbreaks

This system ensures that influenza vaccines are updated annually to match the most likely circulating strains, improving their effectiveness.

Advancements in Production: From Egg-Based to Cell-Based Vaccines

For decades, influenza vaccines were produced using embryonated chicken eggs – a time-consuming process with limitations. In recent years, new technologies have emerged to address these challenges and improve vaccine production.

What are the differences between egg-based and cell-based influenza vaccines?

• Egg-based vaccines:
  • Traditional method used since the 1940s
  • Viruses grown in fertilized chicken eggs
  • Production takes several months
  • Limited by egg supply and allergies
• Cell-based vaccines:
  • Newer technology approved in 2012
  • Viruses grown in mammalian cell cultures
  • Faster production time
  • Not dependent on egg supply
  • Suitable for people with egg allergies

Cell-based vaccine technology represents a significant advancement in influenza vaccine production, offering greater flexibility and potentially improved effectiveness.

Modern Innovations: Expanding Influenza Vaccine Options

The 21st century has seen continued innovation in influenza vaccine technology, with new formulations and delivery methods expanding options for immunization.

Recent advancements in influenza vaccines:

1. High-dose vaccines: Contain four times the antigen of standard flu shots, designed to provide stronger immune response in older adults
2. Adjuvanted vaccines: Include an additive to boost immune response, particularly beneficial for older individuals
3. Recombinant vaccines: Produced using genetic technology, without the need for egg-based or cell-based virus growth
4. Intranasal vaccines: Administered as a nasal spray, offering needle-free immunization option

These innovations aim to improve vaccine effectiveness, expand accessibility, and address the needs of specific populations.

Challenges and Future Directions in Influenza Vaccination

Despite significant progress in influenza vaccine development, challenges remain. Researchers continue to work towards more effective and broadly protective vaccines.

What are the current challenges in influenza vaccination?

Key issues facing influenza vaccine development and implementation include:

• Antigenic drift: Continuous small changes in the virus that can reduce vaccine effectiveness
• Antigenic shift: Major changes that can lead to pandemic strains
• Variable effectiveness: Seasonal vaccines typically provide 40-60% protection
• Production time: Current methods still require months of lead time
• Vaccine hesitancy: Misinformation and skepticism affecting uptake

Future directions in influenza vaccine research:

Scientists are exploring several promising avenues for improving influenza vaccines:

1. Universal influenza vaccines: Targeting conserved parts of the virus to provide broad, long-lasting protection
2. mRNA vaccines: Utilizing technology similar to some COVID-19 vaccines for faster production and greater flexibility
3. Improved adjuvants: Developing more potent immune-boosting additives
4. Alternative delivery methods: Exploring microneedle patches and other novel administration techniques
5. Advanced manufacturing: Implementing new technologies for faster, more efficient vaccine production

These ongoing efforts aim to address current limitations and develop more effective tools for preventing influenza infections and their complications.

The Impact of Influenza Vaccination: A Public Health Success Story

While challenges remain, the development and widespread implementation of influenza vaccines represent a significant public health achievement. Annual influenza vaccination programs have saved countless lives and reduced the burden of disease worldwide.

How have influenza vaccines impacted public health?

The positive effects of influenza vaccination include:

• Reduced influenza-related hospitalizations and deaths
• Decreased severity of illness in vaccinated individuals who do contract influenza
• Protection of vulnerable populations, including young children and older adults
• Reduced economic burden from lost productivity and healthcare costs
• Improved preparedness for potential pandemic influenza strains

The history of influenza vaccination demonstrates the power of scientific research, global collaboration, and public health initiatives in combating infectious diseases. From the misguided efforts of the early 20th century to the sophisticated, annually updated vaccines of today, the journey of influenza vaccination continues to evolve, driven by the goal of better protecting global health.

Lessons from History: Influenza Vaccination and Pandemic Preparedness

The history of influenza vaccination offers valuable lessons for addressing future pandemics and emerging infectious diseases. The experiences gained through decades of influenza vaccine development and implementation have shaped our approach to global health security.

How has influenza vaccination history informed pandemic preparedness?

Key lessons from the history of influenza vaccination include:

• The importance of robust global surveillance systems
• The need for flexible, scalable vaccine production capabilities
• The value of international cooperation in addressing global health threats
• The critical role of public health communication and education
• The benefits of continuous innovation in vaccine technology

These lessons have been applied to recent pandemic responses, including the rapid development of COVID-19 vaccines. The infrastructure and expertise developed for influenza vaccination have provided a foundation for addressing new viral threats.

Applying influenza vaccination strategies to other diseases:

The success of influenza vaccination programs has influenced approaches to other infectious diseases:

1. Annual vaccination model: Considering regular boosters for diseases with evolving strains
2. Global strain monitoring: Implementing surveillance systems for other pathogens
3. Rapid vaccine updates: Developing platforms for quick adaptation to new variants
4. Multi-strain vaccines: Exploring combination vaccines for related pathogens
5. Universal vaccine concepts: Researching broadly protective vaccines for other virus families

As we face ongoing and emerging health threats, the history of influenza vaccination serves as both a guide and an inspiration for future efforts in disease prevention and control.

The journey from the mistaken bacterial theories of the early 20th century to today’s sophisticated influenza vaccines represents a triumph of scientific inquiry and public health innovation. While challenges remain, the continuous improvement of influenza vaccines demonstrates the power of persistent research, global collaboration, and adaptive strategies in combating infectious diseases.

As we look to the future, the lessons learned from nearly a century of influenza vaccination efforts will undoubtedly continue to inform and guide our responses to new and evolving health threats. The history of influenza vaccination is not just a story of past achievements, but a roadmap for ongoing progress in protecting global health.

History of influenza vaccination

History of influenza vaccination

• All topics »
• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z
• Resources »
  • Fact sheets
  • Facts in pictures
  • Multimedia
  • Publications
  • Questions & answers
  • Tools and toolkits
• Popular »
  • Air pollution
  • Coronavirus disease (COVID-19)
  • Hepatitis
  • Monkeypox
• All countries »
• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z
• Regions »
  • Africa
  • Americas
  • South-East Asia
  • Europe
  • Eastern Mediterranean
  • Western Pacific
• WHO in countries »
  • Statistics
  • Cooperation strategies
  • Ukraine emergency
• All news »
  • News releases
  • Statements
  • Campaigns
  • Commentaries
  • Events
  • Feature stories
  • Speeches
  • Spotlights
  • Newsletters
  • Photo library
  • Media distribution list
• Headlines »
• Focus on »
  • Afghanistan crisis
  • COVID-19 pandemic
  • Northern Ethiopia crisis
  • Syria crisis
  • Ukraine emergency
  • Monkeypox outbreak
  • Greater Horn of Africa crisis
• Latest »
  • Disease Outbreak News
  • Travel advice
  • Situation reports
  • Weekly Epidemiological Record
• WHO in emergencies »
  • Surveillance
  • Research
  • Funding
  • Partners
  • Operations
  • Independent Oversight and Advisory Committee
  • WHO’s Health Emergency Appeal 2023
• Data at WHO »
  • Global Health Estimates
  • Health SDGs
  • Mortality Database
  • Data collections
• Dashboards »
  • COVID-19 Dashboard
  • Triple Billion Dashboard
  • Health Inequality Monitor
• Highlights »
  • Global Health Observatory
  • SCORE
  • Insights and visualizations
  • Data collection tools
• Reports »
  • World Health Statistics 2022
  • COVID excess deaths
  • DDI IN FOCUS: 2022
• About WHO »
  • People
  • Teams
  • Structure
  • Partnerships and collaboration
  • Collaborating centres
  • Networks, committees and advisory groups
  • Transformation
• Our Work »
  • General Programme of Work
  • WHO Academy
  • Activities
  • Initiatives
• Funding »
  • Investment case
  • WHO Foundation
• Accountability »
  • Audit
  • Programme Budget
  • Financial statements
  • Programme Budget Portal
  • Results Report
• Governance »
  • World Health Assembly
  • Executive Board
  • Election of Director-General
  • Governing Bodies website
  • Member States Portal
• Home/
• Newsroom/
• Spotlight/
• History of Vaccination/
• History of influenza vaccination

A year-round disease affecting everyone

 

What is influenza?

We know now that influenza, or flu, is caused by a virus – but for
many years it was thought to be caused by a bacterial infection. In 1892, German scientist Richard Pfeiffer isolated a small bacterium from the noses of patients with flu, naming it ‘bacillus influenzae’. 

Early attempts at a vaccine during the 1918 influenza pandemic were based on this understanding, and it was not until the 1930s, when the influenza virus was identified, that progress towards an effective vaccine could really begin. 

Influenza – also known as the ‘flu’ – is a highly contagious respiratory illness, which spreads easily through the air or when people touch contaminated surfaces. In many cases the disease is mild, with symptoms such as chills,
fever and fatigue, and it can also be spread through asymptomatic infections in people who do not even know they are sick. 

But the flu can also result in serious complications, particularly in vulnerable people like young children, older persons, pregnant women and people with medical conditions such as asthma, diabetes or heart disease. The most common complication is
pneumonia, typically caused by a secondary bacterial infection.  

Flu viruses mutate very rapidly, and uncontrolled spread gives rise to many different strains, which fall into 2 main types affecting humans – influenza A and influenza B.

 

© National Museum of Health and Medicine

Emergency hospital during influenza epidemic, Camp Funston, Kansas (1918).

©
Credits

 

“The mother of all pandemics”

The h2N1 influenza pandemic that swept across the world from 1918 to 1919, sometimes called “the mother of all pandemics”, involved a particularly virulent new strain of the influenza A virus. The first wave of infections in early 1918
resulted in mild illness, but a second wave later that year was more deadly. 

The 1918 pandemic is estimated to have infected 500 million people worldwide, killing between 20 and 50 million. The resulting death rates were so high that life expectancy rates around the world dropped by several years, and more people are thought
to have died as a result of the flu pandemic than over the course of the entire First World War.  

Researchers in the United States and Europe raced to find an effective vaccine against influenza during the pandemic years, and their efforts produced hundreds of thousands of doses – but they were targeting the wrong pathogen. 

 

© WHO, Eric Schwab

The day starts at the World Influenza Centre, London, with a conference between Dr C.E. Andrews, Director (right), and his assistant Dr A.A Isaacs

©
Credits

 

Progress toward a vaccine

In 1933, British researchers Wilson Smith, C.H. Andrewes and P.P. Laidlaw at London’s National Institute for Medical Research (NIMR) made a breakthrough when they isolated and identified the influenza virus. They found no bacteria in throat
washings from patients with influenza and discovered that the disease was caused by a virus. 

With support from the US Army, the first inactivated flu vaccine was developed by Thomas Francis and Jonas Salk at the University of Michigan. The vaccine was tested for safety and efficacy on the US military, before being licensed for wider use in
1945.

 

© WHO, Eric Schwab

Miss H.B. Donald of Melbourne, Australia at the Siemeus electron microscope

©
Credits

 

Multiple strains

Researchers had long suspected that different types of influenza viruses existed, as the blood of some influenza patients did not develop antibodies to the strain isolated in 1933. During the testing period, scientists also discovered the existence
of another strain of the virus: influenza B. 

In 1942, a new bivalent vaccine was developed that protected against both the h2N1 strain of influenza A and the newly discovered influenza B virus. 

During the 1947 flu season, researchers discovered that existing vaccines were ineffective against the flu viruses circulating at the time. To investigate the viruses in circulation, the World Health Organization (WHO) established the Worldwide Influenza Centre in 1948 and the Global Influenza Surveillance and Response System (GISRS) in 1952.  

Scientists could now manufacture vaccines based on the monitoring of virus strains in circulation around the world, updating the strains targeted by the vaccine in response. 

Efforts to track the evolution and emergence of flu viruses continue today, and scientists monitor both seasonal and potentially pandemic flu strains. Because new strains appear frequently, the seasonal flu vaccine usually changes each year, as scientists
determine how the virus has mutated and spread. 

Each year, WHO recommends virus strains for inclusion in flu vaccines for each hemisphere, and different vaccines are developed, targeting 3 or 4 strains of the virus predicted to be most commonly circulating in the coming flu season. 

 

© CDC

This historic image depicts a line of people each awaiting a New Jersey Influenza vaccination. Also known as the Swine Flu, this image was captured during a 1976 immunization campaign

©
Credits

 

Potential for pandemics

Influenza pandemics have occurred throughout history: records document at least 3 well before the 1918–19 pandemic, and another 3 have taken hold after, in 1957–58, 1968–69 and 2009–10.  

Influenza viruses with pandemic potential regularly emerge, but not all go on to cause a pandemic. WHO works to monitor influenza viruses with pandemic potential and to prepare for future influenza pandemics.

 

© WHO, Noor Images, Olga Kravets

Lyon, France, 9 March 2022; Institute of infectious agents, University Hospital Lyon. A lab technician at work, seen through the automated PCR system instrument

©
Credits

 

Continued efforts

Researchers are constantly working to develop new vaccine technologies to keep a step ahead of the viruses.

A live attenuated vaccine delivered in the form of a nasal spray was first licensed in 2003, a vaccine using recombinant DNA technology was approved in 2013, and additional influenza vaccines based on newer technologies are being tested in clinical
trials. 

Despite these efforts, seasonal influenza still kills up to 650 000 people a year globally. Influenza is a constantly evolving virus, and immunity to a single strain through infection or vaccination does not necessarily protect against new strains
that develop. 

We know from experience there is likely to be another flu pandemic, and we should be as well prepared as possible when it happens. That’s why monitoring the virus and keeping up with vaccination is crucially important. 

Watch this video to learn more about the history, symptoms and treatment of Influenza.

 

Related history of vaccination stories

Influenza Historic Timeline | Pandemic Influenza (Flu)






Print

Below is a historical timeline of major scientific and public health events and milestones in influenza prevention.

• Timelineicon

  1930s

  • Influenza viruses are isolated from people, proving that influenza is caused by a virus not a bacterium.
    • Smith, Andrewes, and Laidlaw isolate influenza A virus in ferrets in 1933
    • Francis isolates influenza B virus in 1936
    • In 1936, Burnet discovers that influenza virus can be grown in embryonated hens’ eggs.

• Timelineicon

  1940s

  • 1940s: Thomas Francis, Jr., MD and Jonas Salk, MD serve as lead researchers at the University of Michigan to develop the first inactivated flu vaccine with support from the U.S. Army. Their vaccine uses fertilized chicken eggs in a method that is still used to produce most flu vaccines today. The Army is involved with this research because of their experience with troop loss from flu illness and deaths during WWI. This original vaccine only includes an inactivated influenza A virus.
  • 1940s: First-generation mechanical ventilators become available. These machines support breathing in patients suffering respiratory complications.
  • 1940: Influenza B viruses are discovered.
  • 1942: A bivalent (two component) vaccine that offers protection against influenza A and influenza B viruses is produced after the discovery of influenza B viruses.
  • 1944: Use of cell cultures for virus growth is discovered. This allows viruses to be cultured outside the body for the first time. The ability to culture influenza from respiratory secretions allows diagnosis of influenza.
  • 1945: Inactivated influenza vaccine is licensed for use in civilians.
  • 1942: The Communicable Disease Center (CDC) opens in the old offices of the Malaria Control in War Areas, located on Peachtree Street in Atlanta, Georgia with a satellite campus in Chamblee. Launched with fewer than 400 employees, the organization—today the Centers for Disease Control and Prevention–moves to its current main campus on Clifton Road in Atlanta in 1947 after paying $10 to Emory University for 15 acres of land.
  • 1947: During the seasonal flu epidemic of 1947, investigators determine that changes in the antigenic composition of circulating influenza viruses has rendered existing vaccines ineffective, highlighting the need for continuous surveillance and characterization of circulating flu viruses.
  • 1948: The World Health Organization (WHO) Influenza Centre is established at the National Institute for Medical Research in London. The primary tasks of the organization are to collect and characterize influenza viruses, develop methods for the laboratory diagnosis of influenza virus infections, establish a network of laboratories, and disseminate data accumulated from their investigations.

• Timelineicon

  1950s

  • 1952: The Global Influenza Surveillance and Response System (GISRS) is created by WHO to monitor the evolution of influenza viruses. The GISRS network originally includes 26 laboratories.
  • 1956: The CDC’s Influenza Branch in Atlanta is designated a WHO Collaborating Centre for Surveillance, Epidemiology & Control of Influenza.
  • 1957: A new h3N2 flu virus emerges to trigger a pandemic. There are about 1.1 million deaths globally, with about 116,000 in the U.S.

• Timelineicon

  1960s

  • 1960: In 1960, the US Surgeon General, in response to substantial morbidity and mortality during the 1957–58 pandemic, recommends annual influenza vaccination for people with chronic debilitating disease, people aged 65 years or older, and pregnant women.
  • 1961: An outbreak in South Africa raises possibility of wild birds as a possible reservoir for influenza A viruses.
  • 1962: CDC launches the 122 Cities Mortality Reporting System. Each week, the vital statistics office of 122 cities across the U.S. report the total number of death certificates processed and the number of those for which pneumonia or influenza is listed as an underlying or contributing cause of death by age group. The system is retired in October 2016.
  • 1966:  The FDA licenses amantadine, a new antiviral medication, as a prophylactic (preventive medicine) against influenza A. It isn’t effective against influenza B.
  • 1967: Dr. H.G. Pereira and colleagues propose a relationship between human and avian flu viruses after a study shows an antigenic relationship between the 1957 human pandemic A virus and an influenza A virus isolated from a turkey. The study raises the question and triggers the body of work on whether human influenza viruses are of avian origin.
  • 1968: A new h4N2 influenza virus emerges to trigger another pandemic, resulting in roughly 100,000 deaths in the U.S. and 1 million worldwide. Most of those deaths are in people 65 and older. h4N2 viruses circulating today are descendants of the h4N2 virus that emerges in 1968.

• Timelineicon

  1970s

  • An h2N1 (swine flu) outbreak among recruits at Fort Dix leads to a vaccination program to prevent a pandemic. Within 10 months, roughly 25% of the US population is vaccinated (48 million people), about twice the level needed to provide coverage for the at-risk population. Cases of Guillain-Barre syndrome, a neurologic condition that in rare instances has been associated with vaccination, among vaccine recipients appeared to be in excess of what was expected, so officials determine the vaccination program should be halted.  1981: CDC begins collecting reports of influenza outbreaks from state and territorial epidemiologists.

• Timelineicon

  1990s

  • 1993: The Vaccines for Children (VFC) Program is established as a result of a measles outbreak to provide vaccines at no cost to children whose parents or guardians might not be able to afford them. The program increases the likelihood of children getting recommended vaccinations on schedule.
  • 1993: The costs of influenza vaccine become a covered benefit under Medicare Part B.
  • 1994: Rimantadine, derived from amantadine, is approved by the FDA to treat influenza A.
  • 1996: An avian influenza H5N1 virus is first isolated from a farmed goose in China.
  • 1997: The first human infection with an avian influenza A H5N1 virus is identified in Hong Kong.
  • 1997: FluNet, a web-based flu surveillance tool, is launched by WHO. It is a critical tool for tracking the movement of flu viruses globally. Country data is updated weekly and is publically available.
  • 1998: Influenza virus surveillance in swine, conducted by the US Department of Agriculture, begins in the United States. A virus that is a hybrid of human, bird and swine flu viruses is detected in pigs. This virus becomes the dominant flu virus in U.S. pigs by 1999.
  • 1999: A pandemic planning framework is published by WHO emphasizing the need to enhance influenza surveillance, vaccine production and distribution, antiviral drugs, influenza research and emergency preparedness
  • 1999: The neuraminidase inhibitors oseltamivir (Tamiflu®) and zanamivir (Relenza®) are licensed to treat influenza infection.

• Timelineicon

  2000s

  • April 2002: The Advisory Committee on Immunization Practices (ACIP) encourages that children 6 to 23 months of age be vaccinated annually against influenza.
  • 2003: Public health officials are concerned about a re-emergence of H5N1 avian influenza reported in China and Vietnam.
  • June 2003: The first nasal spray flu vaccine is licensed.
  • 2004: The National incident Management System (NIMS) is established to coordinate response for public health incidents that require actions by all levels of government, as well as public, private, and nongovernmental organizations.
  • 2005: The US. Government National Strategy for Pandemic Influenza is published
  • 2005: The entire genome of the 1918 h2N1 pandemic influenza virus is sequenced
  • 2006: CDC stops recommending adamantanes during the 2005-2006 season after high levels of resistance among influenza A viruses. In the US, resistance increased from 1.9% during the 2003-2004 season to 11% in the 2004-2005 season.
  • 2006: The National Strategy for Pandemic Influenza Implementation Plan is published. The document outlines U.S. preparedness and response to prevent the spread of a pandemic.
  • 2007: The American Veterinary Medical Association (AVMA) establishes the One Health initiative Task Force, an effort to attain optimal health for people, animals, and the environment.
  • 2007: The American Medical Association unanimously approves a resolution calling for increased collaboration between human and veterinary medical communities. The term ‘one health,’ which looks at the interactions between animal and human health, enters the medical and scientific lexicon.
  • 2007: The One Health approach is recommended for pandemic preparedness during the International Ministerial Conference on Avian and Pandemic Influenza
  • 2007: FDA approves the first U.S. vaccine for people against an avian influenza A(H5N1) virus.
  • 2007: Human infection with a novel influenza virus is added to the nationally notifiable disease list
  • 2008:  ACIP expands its influenza vaccination recommendation to include vaccination of children ages 5-18 years.
  • 2008: HHS Pandemic Influenza Operational Plan is published
  • 2008: CDC receives US Food and Drug Administration approval for a highly sensitive influenza polymerase chain reaction (PCR) assay. These tests can detect influenza with high specificity that enhances diagnosis and treatment options.
  • 2008: The Influenza Reagent Resource (IRR) is established by CDC to provide registered users with reagents, tools, and information to study and detect influenza viruses
  • April 17, 2009:  A new h2N1 virus is detected in the U.S.
  • CDC begins working to develop a virus (called a candidate vaccine virus) that could be used to make vaccine to protect against this new virus.
  • April 25, 2009: The World Health Organization (WHO) declares a public health emergency of international concern.
  • June 11, 2009: WHO officially declares the new 2009 h2N1 outbreak a pandemic.
  • 2009: CDC begins a complex and multi-faceted response to the h2N1 pandemic which lasts more than a year.
  • 2009: Physicians use point of care rapid immunoassay tests to provide influenza results within 15 minutes during the h2N1 pandemic
  • October 5, 2009: The first doses of monovalent h2N1 pandemic vaccine are administered.

• Timelineicon

  2010s

  • August 10, 2010: WHO declares an end to 2009 h2N1 influenza pandemic.
  • 2010:  The ACIP recommends annual influenza vaccination for those 6 months of age and older.
  • 2012: Vaccines containing cell-cultured virus become available. Even though eggs continue to be the primary means of production, cell culture emerges as an alternative method for producing influenza vaccines.
  • 2012: WHO makes first vaccine composition recommendation for a quadrivalent vaccine.
  • 2012: CDC partners with Association of Public Health laboratories to define the optimal right size for influenza virologic surveillance. The project produces right-size calculators; statistical tools that help states determine the optimal amount of influenza testing needed for desired confidence levels of surveillance.
  • 2014: The FDA approves peramivir (Rapivab) to treat influenza in adults. It is the first IV flu medication.
  • 2017: CDC updates guidelines for use of non-pharmaceutical measures to help prevent spread of pandemic influenza based on latest scientific evidence. These are actions that individuals and communities can take to help slow spread of the flu like staying home when sick, covering a cough or sneeze, and frequently washing hands.






Why you should get a flu shot

Influenza is an acute viral disease that can affect the upper and lower respiratory tract, is accompanied by severe intoxication and can lead to serious complications and deaths, mainly in the elderly and children. In temperate areas, seasonal epidemics occur mainly during the winter season, while in tropical areas, influenza viruses circulate all year round, leading to less regular epidemics.

Influenza is ubiquitous globally, with annual infection rates estimated at 5%-10% in adults and 20%-30% in children.

The flu has been known to mankind for centuries. The first documented influenza epidemic occurred in 1580. True, at that time nothing was known about the nature of this disease. The pandemic of respiratory infection in 1918-1920, which took over the globe, and was called the “Spanish flu”, most likely was nothing more than an epidemic of severe influenza. It is known that the Spaniard was distinguished by incredible mortality – with lightning speed it led to pneumonia and pulmonary edema, even in young patients.

Reliably the viral nature of influenza was established in England only in 1933 by Smith, Andrews and Laidlaw. In 1940, Francis and Magil discovered the influenza B virus, and in 1947, Taylor isolated another new variant of the influenza virus, C. Since 1940, it became possible to actively study the influenza virus and its properties – the virus began to be grown in chicken embryos. Since then, a big step forward has been made in the study of influenza – the ability to mutate has been discovered, and all parts of the virus capable of variability have been identified. An important discovery, of course, was the creation of a vaccine against influenza.

Influenza can cause severe complications in high risk groups such as:

• pneumonia (bacterial and hemorrhagic), pleural empyema, lung abscess (may lead to lung failure),

• from the cardiovascular system – myocarditis, pericarditis (may lead to heart failure),

• from the nervous system – meningitis, meningoencephalitis, encephalitis, neuritis, neuralgia, polyradiculoneuritis,

• from the ENT organs – otitis media, sinusitis, rhinitis, tracheitis,

• from the muscular system – myositis,

• glomerulonephritis, Reye’s syndrome, toxic-allergic shock, etc.

The most effective way to prevent the disease or its severe consequences is vaccination .

Vaccination is especially important for people from high-risk groups development of serious complications of influenza, as well as for people living with or caring for people from high-risk groups.

The Federal Service for Supervision of Consumer Rights Protection and Human Welfare (Rospotrebnadzor) recommends annual vaccination for the following population groups:

• Persons suffering from chronic cardiovascular diseases: especially congenital and acquired heart defects (especially mitral stenosis).

• Persons suffering from chronic lung diseases (including bronchial asthma).

• Patients with diabetes.

• Patients with chronic diseases of the kidneys and blood.

• Pregnant women.

• Older people over 65 years of age, because in most cases they have chronic diseases in varying degrees.

• Children under 2 years old.

Influenza vaccination minimizes not only the likelihood of getting sick, but also, most importantly, the possibility of complications. In addition, vaccination facilitates the course of the disease. Influenza vaccines have been shown to be effective in all age groups.